On December 5, 2024, MediciNova, Inc. (MNOV) announced a study update and interim analysis from the Phase 2b/3 COMBAT-ALS trial were scheduled to be presented at the 35th International Symposium on ALS/MND. As of Nov. 15, 2024, 217 participants had been enrolled and 183 participants were assigned to either MN-166 or placebo. Positive correlations were seen between the 6-month and 12-month data for the Combined Assessment of Function and Survival (CAFS) scores (0.71), modified CAFS score (0.70), and ASLFRS-R (0.69). The DSMB has recommended that the trial continue as per the protocol. Based on current enrollment, the study is expected to be fully enrolled by mid-2025 and trial results should be reported in 2026.
